An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn increasing interest from consumers seeking alternatives to standard drugs. Researchers say peptide treatments could reshape approaches to resistant infections, though concerns about quality persist. The committee's endorsement of six peptides paves the way for more broad prescribing, even as critics warn of short-term evidence. Industry analysts note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on some peptide candidates.